Oncology and Cancer Immunology Partnering Interests
Working together with our collaboration partners, Boehringer Ingelheim is leading the way in the search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities in oncology and cancer immunology. Our growing portfolio of partnerships includes a large number of collaborations with academic partners and biotechnology companies and we are actively pursuing new early-science collaborations in our areas of partnering interest.
Our experience
Our ambition is to deliver first-in-class treatments that can transfprm patients' lives. We are advancing a comprehensive clinical development pipeline of around 20 projects including cancer cell-directed agents, immune oncology therapies and smart combination approaches. These are being developed in various cancers and tumor types and include multiple new biological entities and new chemical entities. We are poised for the next wave of innovation with clinical phase projects involving novel modalities such as oncolytic viruses, cancer vaccines and T-cell engagers.
Our commitment to innovation in oncology research has already resulted in the launch of two pioneering treatments for non-small cell lung cancer.
Located in Germany, Austria, Switzerland and the USA, our dedicated oncology research centers are the hubs for our cancer R&D activities where our scientists, working together with our innovation partners, have the ambition to identify and translate the most promising scientific breakthroughs into clinical applications for patients across a wide range of cancers.
Our research focus
Our research in oncology and cancer immunology has two major focus areas:
- Cancer cell-directed therapies
- Immune cell-directed therapies
Our partnering interests
We are seeking in-licensing and collaborative opportunities at discovery, pre-clinical and clinical stages, for therapeutic programs in our interest areas.
- Cancer cell-directed therapies: Genetically-validated cancer drivers; DNA damage control pathway; Transcriptional regulation; Novel ADC targets and payloads; Degrader approaches
- Cancer immunology approaches: Turning cold tumors hot including myeloid and T cell-modulating therapies; Novel T cell engagers; Novel tumor antigen identification platforms; TCR identification and TCRm antibodies; Tumor stromal concepts
Disease area focus
- Solid tumors, particularly gastrointestinal cancers (colorectal, gastric, esophageal, stomach, liver, pancreas) and lung cancers
- Prostate cancer, glioblastoma
Related Content
